Windtree Therapeutics
Windtree Therapeutics, headquartered in Warrington, PA, focuses on developing innovative treatments for oncology and cardiovascular diseases, and is listed on NASDAQ under the ticker symbol WINT.
Company Overview
Windtree Therapeutics is focused on developing innovative treatments for oncology and cardiovascular diseases. The company is listed on NASDAQ under the ticker symbol WINT. The company is headquartered in Warrington, PA, with additional operations in Taiwan and Milan, Italy.
Pipeline and Products
Windtree Therapeutics is currently developing several novel therapies aimed at improving patient outcomes in oncology and cardiovascular treatments. Key products in their pipeline include istaroxime, a first-in-class therapy designed to improve cardiac function, and rostafuroxin, which targets genetically associated hypertension. Additionally, the company is working on SERCA2a activators and aPKCi inhibitors.
Strategic Alliances and Licensing
Windtree Therapeutics is engaged in strategic alliances and licensing agreements to advance its product portfolio. Notably, the company has out-licensed global rights for AEROSURF and KL4 surfactant technology.
Global Operations
Windtree Therapeutics operates globally with headquarters in Warrington, PA and additional operations in Taiwan and Milan, Italy. This international presence allows the company to effectively manage its R&D and commercial activities across different regions.